Related Experiment Video
Updated: Jan 27, 2026

Refined Murine Model of Idiopathic Pulmonary Fibrosis
Published on: June 17, 2025
Molecular endpoints for establishing target engagement by novel idiopathic pulmonary fibrosis therapies
Paul J Wolters1, Vincent Cottin2
1Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Dept of Medicine, University of California, San Francisco, San Francisco, CA, USA paul.wolters@ucsf.edu.
No abstract available in PubMed .
More Related Videos
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
06:29Adoptive Transfer of IL-33-Stimulated Macrophages into Bleomycin-Induced Mouse Models to Study Their Effect on Idiopathic Pulmonary Fibrosis In Vivo
Published on: May 5, 2023
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Precipitation Titration: Endpoint Detection Methods
In the Volhard method, a standard excess of AgNO3 is first added to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Molecular Models
Gene Therapy